Trials / Completed
CompletedNCT04531709
Financial Toxicity and Quality of Life in Patients With TGCT
Financial Toxicity and Quality of Life in Patients With Testicular Germ Cell Tumors
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 24 (actual)
- Sponsor
- The University of Texas Health Science Center at San Antonio · Academic / Other
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a cross-sectional, observational study employing validated questionnaires to investigate financial toxicity in subjects with testicular germ cell tumors (TGCT). As background, TGCTs are the most common malignancies among men from age 15-35. Treatment is highly curative, but often consists of intensive multi-cycle chemotherapy with significant potential for physical toxicity. The treatment course itself is disruptive and long term physical and mental health consequences can increase risk for financial toxicity. Thus, we aim to study financial toxicity in both patients with TGCT actively receiving treatment and in TGCT survivors. There will be two separate cohorts: Cohort 1 will consist of subjects with recently diagnosed TGCT who will undergo multi-agent, multi-cycle chemotherapy and Cohort 2 will consist of subjects who have completed chemotherapy and are long-term survivors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Comprehensive Score for financial toxicity (COST) | Measure indirect and direct health care cost that burden patients and their loved ones. |
| OTHER | Functional Assessment of Cancer Therapy: General (FACT-G) | General quality of life instrument |
| OTHER | EORTC QLQ C-30 | Assess quality of life in cancer patients |
| OTHER | EORTC QLQ-TC26. | To measure disease and treatment related quality of life issues relevant to testicular cancer patients that were not explored in the QLQ-C30 questionnaire. |
Timeline
- Start date
- 2023-03-01
- Primary completion
- 2025-02-04
- Completion
- 2025-02-04
- First posted
- 2020-08-28
- Last updated
- 2025-07-14
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT04531709. Inclusion in this directory is not an endorsement.